The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lemeshko A.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Gevorkov A.R.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Boiko A.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Polyakov A.P.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia;
I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia

Titova O.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Gashimova P.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Individualization of treatment policy for patients with regional metastatic oropharyngeal carcinoma associated with human papillomavirus

Authors:

Lemeshko A.M., Gevorkov A.R., Boiko A.V., Polyakov A.P., Titova O.A., Gashimova P.N.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(6): 65‑72

DOI: 10.17116/onkolog20221106165

Read: 1665 times

Download PDF (RU)
Contact the author
Table of contents

INDIVIDUALIZATION OF TREATMENT POLICY FOR PATIENTS WITH REGIONAL METASTATIC OROPHARYNGEAL CARCINOMA ASSOCIATED WITH HUMAN PAPILLOMAVIRUS
INDIVIDUALIZATION OF TREATMENT POLICY FOR PATIENTS WITH REGIONAL METASTATIC OROPHARYNGEAL CARCINOMA ASSOCIATED WITH HUMAN PAPILLOMAVIRUS

To cite this article:

Lemeshko AM, Gevorkov AR, Boiko AV, Polyakov AP, Titova OA, Gashimova PN. Individualization of treatment policy for patients with regional metastatic oropharyngeal carcinoma associated with human papillomavirus. P.A. Herzen Journal of Oncology. 2022;11(6):65‑72. (In Russ.)
https://doi.org/10.17116/onkolog20221106165

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of the clinical course of biological subtypes of squamous cell oropharyngeal carcinoma. P.A. Herzen Journal of Onco­logy. 2025;(1):58-62
Sepa­ration surgery in the treatment of spinal meta­stases. P.A. Herzen Journal of Onco­logy. 2025;(1):63-69
Surgical access for thoracic and intrathoracic goiter. Piro­gov Russian Journal of Surgery. 2025;(1):54-61
En plaque convexity hype­rostotic meni­ngioma: 69 cases from a singlecenter. Burdenko's Journal of Neurosurgery. 2025;(1):20-29
Treatment of patients with exte­rnal inte­stinal fistulas and wide­spread peri­toneal adhe­sions. Piro­gov Russian Journal of Surgery. 2025;(2):44-49
Pregnancy in the «niche» of the scar on the uterus after cesa­rean section: the volu­mes of surgical treatment. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):37-43
Clinical effi­cacy and effect of neodymium laser on biomechanical properties of the vagi­nal wall in patients with grade I—II pelvic organ prolapse. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):50-58
Surgical treatment of pulmonary tube­rculosis in children and adolescents. Piro­gov Russian Journal of Surgery. 2025;(3):16-23
Phage therapy analysis of effe­ctiveness in como­rbid patients with wounds and surgical infe­ctions of various etiology based on the resu­lts of a comparative clinical study. Piro­gov Russian Journal of Surgery. 2025;(3):124-138
Controversial issues of colon stenting in case of tumor obstructive inte­stinal obstruction: surgical and onco­logical aspe­cts. Endo­scopic Surgery. 2025;(2):65-75
Abstract:

The review is devoted to the problem of management tactics for patients with locally advanced oropharyngeal cancer. The problem is extremely relevant now due to the lack of a unified approach. Despite the fact that radiation and chemoradiotherapy are main treatments for cancer; some cases require subsequent surgical intervention into the primary focus and/or regional lymph collectors. Thus, regardless of the antitumor effect of chemoradiotherapy, the principle of mandatory cervical lymphadenectomy for patients with regional metastatic oropharyngeal cancer was common in Russian practice. However, the validity of these approaches is questioned today. On the one hand, patients with HPV-positive oropharyngeal cancer constitute a special group of patients with a favorable prognosis, a high tumor radiosensitivity, which indicates the prospects for de-escalation of antitumor treatment, the ability to refrain from cervical lymphadenectomy in particular. On the other hand, negative predictors, such as extracapsular extension, N3, and a significant (more than 10 pack-year) smoking history, can level off a favorable prognosis and, perhaps, it is in this patient cohort that more aggressive approaches can be applied to. Determination of clear indications for cervical lymphadenectomy as part of combination treatment is promising in terms of both enhancing the efficiency of antitumor treatment and maintaining quality of life. The review presents foreign experts’ current views on the prognostic significance of predictors for an incomplete regional response in oropharyngeal squamous cell carcinoma and on the individualization of indications for cervical lymphadenectomy.

Keywords:

oropharyngeal squamous cell carcinoma
human papillomavirus
p16 protein expression
chemoradiotherapy
surgical treatment
cervical lymphadenectomy

Authors:

Lemeshko A.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Gevorkov A.R.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Boiko A.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Polyakov A.P.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia;
I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia

Titova O.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Gashimova P.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

09.06.2022

Accepted:

04.07.2022

Close metadata

References:

  1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301. https://doi.org/10.1200/jco.2011.36.4596
  2. Karpenko AV, Sibgatullin RR, Boiko AA, Chumanikhina NS, Lomteva EYu, Lavrova MV, Kostova MG, Nikolayeva OM. Surgery for advanced oropharyngeal cancer. Head and Neck Tumors (HNT). 2018;8(3):37-45. (In Russ.). https://doi.org/10.17650/2222-1468-2018-8-3-37-45
  3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209-249.  https://doi.org/10.1002/cam4.1045
  4. Wang F, Zhang H, Xue Y, Wen J, Zhou J, Yang X, Wei J. A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas. Cancer Med. 2017;6(5):910-917.  https://doi.org/10.1002/cam4.1045
  5. Mariz BALA, Kowalski LP, William WN Jr, de Castro G Jr, Chaves ALF, Santos M, de Oliveira TB, Araújo ALD, Normando AGC, Ribeiro ACP, et al.; Latin American Cooperative Oncology Group — Brazilian Group of Head and Neck Cancer. Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;156:103116. https://doi.org/10.1016/j.critrevonc.2020.103116
  6. Chen AM, Zahra T, Daly ME, Farwell DG, Luu Q, Gandour-Edwards R, Vaughan AT. Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer. Head Neck. 2013;35(11):1652-1656. https://doi.org/10.1002/hed.23209
  7. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-269.  https://doi.org/10.1093/jnci/djn011
  8. Huang SH, Perez-Ordonez B, Weinreb I, Hope A, Massey C, Waldron JN, Kim J, Bayley AJ, Cummings B, Cho BCJ, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49(1):79-85.  https://doi.org/10.1016/j.oraloncology.2012.07.015
  9. Wuerdemann N, Jain R, Adams A, Speel EJM, Wagner S, Joosse SA, Klussmann JP. Cell-free HPV-DNA as a biomarker for oropharyngeal squamous cell carcinoma — a step towards personalized medicine? Cancer (Basel). 2020;12(10):2997. https://doi.org/10.3390/cancers12102997
  10. Marmiroli L, Ausili-Cèfaro G, Nardone L, Fiorentino G, Genovesi D, Salvi G. Combined radiochemotherapy for organ preservation in head and neck cancer: review of literature and personal experience. Rays. 1997;22(3):425-440. 
  11. Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39(9):956-965.  https://doi.org/10.1200/jco.20.03128
  12. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx — ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35(5);490-497.  https://doi.org/10.1200/jco.2016.68.3300
  13. Cohen EW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735-2743. https://doi.org/10.1200/jco.2013.54.6309
  14. Bhattasali O, Han J, Thompson LDR, Buchschacher GL Jr, Abdalla IA, Iganej S. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. Oral Oncol. 2018;78:151-155.  https://doi.org/10.1016/j.oraloncology.2018.01.031
  15. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516-525.  https://doi.org/10.1038/nrc1650
  16. Konstantinova YuS, Shavrina YuA. Regional chemotherapy in treatment of patients with locally advanced squamous cell head and neck cancer. Al’manakh sovremennoi nauki i obrazovaniya. 2015;6:91-96. (In Russ.).
  17. Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA, Roman BR. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer. 2016;122(10):1523-1532. https://doi.org/10.1002/cncr.29938
  18. Habbous S, Chu KP, Lau H, Schorr M, Belayneh M, Ha MN, Murray S, O’Sullivan B, Huang SH, Snow S, et al. Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. CMAJ. 2017;189(32):1030-1040. https://doi.org/10.1503/cmaj.161379
  19. Stelmes JJ, Gregoire V, Poorten VV, Golusiñski W, Szewczyk M, Jones T, Ansarin M, Broglie MA, Giger R, Klussmann JP, et al. Organ preservation and late functional outcome in oropharyngeal carcinoma: rationale of EORTC 1420, the «Best of» trial. Front Oncol. 2019;9:999.  https://doi.org/10.3389/fonc.2019.00999
  20. Nichols AC, Lang P, Prisman E, Berthele E, Tran E, Hamilton S, Wu J, Fung K, de Almeida JR, Bayley A, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. BMC Cancer. 2020;20(1):125.  https://doi.org/10.1186/s12885-020-6607-z
  21. Rietbergen MM, Snijders P, Beekzada D, Braakhuis B, Brink A, Heideman DA, Hesselink AT, Witte BI, Bloemena E, Baatenburg-De Jong RJ, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer. 2014;134(10):2366-2372. https://doi.org/10.1002/ijc.28580
  22. Nauta IH, Rietbergen MM, van Bokhoven AAJD, Bloemena E, Lissenberg-Witte BI, Heideman DAM, Baatenburg de Jong RJ, Brakenhoff RH, Leemans CR. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29(5):1273-1279. https://doi.org/10.1093/annonc/mdy060
  23. Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, et al. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol. 2012;23(7):1832-1837. https://doi.org/10.1093/annonc/mdr544
  24. Billfalk-Kelly A, Yu E, Su J, O’Sullivan B, Waldron J, Ringash J, Bartlett E, Perez-Ordonez B, Weinreb I, Bayley A, et al. Radiologic extranodal extension portends worse outcome in cN+ TNM-8 stage I human papillomaviruse-mediated oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;104(5):1017-1027. https://doi.org/10.1016/j.ijrobp.2019.03.047
  25. Chan MW, Yu E, Bartlett E, O’Sullivan B, Su J, Waldron J, Ringash J, Bratman SV, Chen YA, Irish J, et al. Morphologic and topographic radiologic features of human papillomavirus-related and -unrelated oropharyngeal carcinoma. Head Neck. 2017;39(8):1524-1534. https://doi.org/10.1002/hed.24764
  26. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM Jr, Myers JN. Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol. 2006;263(4):313-318.  https://doi.org/10.1007/s00405-005-1016-0
  27. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, Scher RL. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58(5):1418-1423. https://doi.org/10.1016/j.ijrobp.2003.09.004
  28. Apisarnthanarax S, Elliott DD, El-Naggar AK, Asper JA, Blanco A, Ang KK, Garden AS, Morrison WH, Rosenthal D, Weber RS, et al. Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys. 2006;64(3):678-683.  https://doi.org/10.1016/j.ijrobp.2005.08.020
  29. Böscke R, Cakir BD, Hoffmann AS, Wiegand S, Quetz J, Meyer JE. Outcome after elective neck dissection and observation for the treatment of the clinically node-negative neck (cN0) in squamous cell carcinoma of the oropharynx. Eur Arch Otorhinolaryngol. 2014;271(3):567-574.  https://doi.org/10.1007/s00405-013-2545-6
  30. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26(5):447-455.  https://doi.org/10.1002/hed.10394
  31. Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, et al. Establishing quality indicators for neck dissection: correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016;122(22):3464-3471. https://doi.org/10.1002/cncr.30204
  32. Lilja-Fischer JK, Jensen K, Eskildsen HW, Fink-Jensen V, Nielsen VE. Response evaluation of the neck in oropharyngeal cancer: value of magnetic resonance imaging and influence of p16 in selecting patients for post-radiotherapy neck dissection. Acta Oncol. 2015;54(9):1599-1606. https://doi.org/10.3109/0284186x.2015.1063781
  33. Huang SH, O’Sullivan B, Xu W, Zhao H, Chen DD, Ringash J, Hope A, Razak A, Gilbert R, Irish J, et al. Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys. 2013;87(5):1078-1085. https://doi.org/10.1016/j.ijrobp.2013.08.049
  34. Galloway TJ, Zhang QE, Nguyen-Tan PF, Rosenthal DI, Soulieres D, Fortin A, Silverman CL, Daly ME, Ridge JA, Hammond JA, et al. Prognostic value of p16 status on the development of a complete response in involved oropharynx cancer neck nodes after cisplatin-based chemoradiation: a secondary analysis of NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2016;96(2):362-371.  https://doi.org/10.1016/j.ijrobp.2016.05.026
  35. Shonka DC Jr, Shoushtari AN, Thomas CY, Moskaluk C, Read PW, Reibel JF, Levine PA, Jameson MJ. Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status. Arch Otolaryngol Head Neck Surg. 2009;135(11):1126-1132. https://doi.org/10.1001/archoto.2009.153
  36. Wotman M, Ghaly M, Massaro L, Tham T, Seetharamu N, Kamdar D, Frank D, Kraus D, Teckie S. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: an institutional experience. Am J Otolaryngol. 2019;40(5):684-690.  https://doi.org/10.1016/j.amjoto.2019.06.003
  37. Garden AS, Gunn GB, Hessel A, Beadle BM, et al. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014; 120(19): 3082-3088. https://doi.org/10.1002/cncr.28831
  38. Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer. 2012;118(14):3519-3530. https://doi.org/10.1002/cncr.26671
  39. Kann BH, Buckstein M, Carpenter TJ, Bakst R, Misiukiewicz K, Genden E, Posner M, Kostakoglu L, Som P, Gupta V. Radiographic extracapsular extension and treatment outcomes in locally advanced oropharyngeal carcinoma. Head Neck. 2014;36(12):1689-1694. https://doi.org/10.1002/hed.23512
  40. Freitag J, Wald T, Kuhnt T, Gradistanac T, Kolb M, Dietz A, Wiegand S, Wichmann G. Extracapsular extension of neck nodes and absence of human papillomavirus 16‐DNA are predictors of impaired survival in p16‐positive oropharyngeal squamous cell carcinoma. Cancer. 2020;126(9):1856-1872. https://doi.org/10.1002/cncr.32667
  41. Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, Murthy V, Budrukkar A. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(11):2083-2095. https://doi.org/10.1007/s00259-011-1893-y
  42. Liu HY, Milne R, Lock G, Panizza BJ, Bernard A, Foote M, McGrath M, Brown E, Gandhi M, Porceddu SV. Utility of a repeat PET/CT scan in HPV-associated oropharyngeal cancer following incomplete nodal response from (chemo)radiotherapy. Oral Oncol. 2019;88:153-159.  https://doi.org/10.1002/cncr.32667
  43. Ryan U., Tassia G., Robert O., Jonn Wu, Eric B., Eric T., et al. FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status. Radiotherapy and Oncology.2020;148:14-20.  https://doi.org/10.1016/j.radonc.2020.03.032
  44. Daniels CP, Liu HY, Bernard A, Williams C, Foote MC, Ladwa R, McGrath M, Panizza BJ, Porceddu SV. The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer. Radiother Oncol. 2020;151:242-248.  https://doi.org/10.1016/j.radonc.2020.08.004
  45. Huang SH, O’Sullivan B, Xu W, Chen DD, Ringash J, Hope A, Razak A, Gilbert R, Irish J, Kim J, et al. Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys. 2013;87(5):1078-1085. https://doi.org/10.1016/j.ijrobp.2013.08.049
  46. Vainshtein JM, Spector ME, Stenmark MH, Bradford CR, Wolf GT, Worden FP, Chepeha DB, McHugh JB, Carey T, Wong KK, et al. Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014;50(3):234-239.  https://doi.org/10.1002/cncr.32667
  47. Sano D, Yabuki K, Arai Y, Tanabe T, Chiba Y, Nishimura G, Takahashi H, Yamanaka S, Oridate N. The applicability of new TNM classification for humanpapilloma virus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: a single-centre study. Auris Nasus Larynx. 2018;45(3):558-565.  https://doi.org/10.1016/j.anl.2017.07.010
  48. O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440-451.  https://doi.org/10.1016/s1470-2045(15)00560-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.